Dow and Colorcon extend and broaden the scope of the Controlled Release Alliance
Alliance will be extended to include Dow’s advanced technology-based pharmaceutical excipients.
Colorcon and The Dow Chemical Company have agreed to broaden the existing Controlled Release Alliance between the two companies. While the Alliance currently provides controlled release technologies from Dow Pharma & Food Solutions, a business unit of Dow, to customers, effective 1 January 2017, it will be extended to include Dow’s advanced technology-based pharmaceutical excipients.
The Alliance has served the needs of the pharmaceutical industry, since July 2007, providing customized solutions, products and support services for pharmaceutical product development. The addition of new technologies into the Alliance product portfolio expands the existing relationship between Colorcon and Dow and further enables formulation and development of fast-growing pharmaceutical applications, beyond the existing controlled release scope.
“This new phase reaffirms the long-standing commitment between the two companies to grow together and leverage their respective strengths,” said Martti Hedman, CEO of Colorcon Inc. “With the addition of new technologies, we look forward to providing increased value for our pharmaceutical customers, strengthening our market leadership position, and continuing to be their supplier of choice.”
The alliance portfolio will comprise the controlled release technologies including METHOCEL CR Cellulose Ethers, ETHOCEL polymers and POLYOX resins, as well as the additional excipient technologies including AFFINISOL polymers for solubility enhancement, ENTERACT polymers for enteric tablet coatings, and DUOLITE and AMBERLITE ion exchange resins for controlled release and other applications.
AFFINISOL is a new science-driven offering to enhance the solubility profile of poorly soluble active pharmaceutical ingredients, one of the most pressing needs of the pharmaceutical industry today. This innovative technology is ideal for formulating BCS Class II and Class IV compounds via spray dry dispersion or hot melt extrusion, the two leading processing technologies in the field.
In addition, AMBERLITE and DUOLITE are powdered ion exchange resins used as formulation excipients. The technologies have a broad range of applications, including taste-masking, tablet disintegration, modified release and the formulation of poorly soluble or unstable drug compounds.
“The expansion of the Alliance portfolio enables Dow to extend a more robust pharmaceutical offering to a wider base of customers through this collaboration,” said Marc van Gerwen, business director of Dow Pharma & Food Solutions. “Dow’s long standing relationship with Colorcon is rooted in the belief that the company’s innovation and manufacturing excellence is complemented perfectly by Colorcon’s global reach and deep technical expertise.”
The agreement also renews the Alliance innovation partnership, in which Colorcon and Dow collaborate on the development and commercialization of the next generation controlled release excipients. The partnership’s efforts focus on areas such as productivity improvement and manufacturing efficiency for the pharmaceutical industry.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance